Verona Pharma Plc ADR (VRNA)

$104.74 -0.03 (-0.03%)
Market Cap 8.49B
Revenue (ttm) 42.28M
Net Income (ttm) -173.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 469.67
Profit Margin -410.17%
Debt to Equity Ratio 1.07
Volume 6,941,500
Avg Vol 3,609,586
Day's Range N/A - N/A
Shares Out 81.08M
Stochastic %K 99%
Beta 0.24
Analysts Sell
Price Target $110.55

Company Profile

Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 an...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 3283 4200
Address:
3 More London Riverside, London, United Kingdom
Dark_Horse_Investments
Dark_Horse_Investments Jul. 17 at 12:44 AM
$VRNA what joke is Jim Cramer! First burn VRNA caller by saying sell : "co looses a lot of money". Now after a $10B takeout he wants to be in the VRNA conversation. This is why ALWAYS Do your Due Diligence. NEVER trust pundits or analysts of the the bat. https://finance.yahoo.com/news/verona-pharma-plc-vrna-unlikely-180443309.html
0 · Reply
WAJeff
WAJeff Jul. 16 at 2:48 PM
More $HOOD sold at $104. #1 realized gainer ytd, then $GEV and $VRNA (Merck buyout at $107 a share)
0 · Reply
YungBullHOLLA
YungBullHOLLA Jul. 16 at 2:28 PM
$VRNA wish I could holla more
4 · Reply
Kingjake26
Kingjake26 Jul. 16 at 1:49 PM
$IXHL The global market for obstructive sleep apnea (OSA) devices is experiencing substantial growth, driven by increasing awareness, rising prevalence of OSA, and technological advancements. The market is projected to reach $18.30 billion by 2032, with a compound annual growth rate (CAGR) of 8.6% from 2025. North America currently dominates the market, but Asia Pacific is expected to grow the fastest. $XBI $VRNA
1 · Reply
FE123
FE123 Jul. 16 at 9:33 AM
$REPL $VRNA was at $15 after Approval now $105 Sold! $REPL can follow the Same path!
1 · Reply
DipinDipout
DipinDipout Jul. 15 at 9:55 PM
$VRNA has this forum turned into the new promotional thread for stock whisperers to pump on? What the what, enough already…drop a note if you’re so inclined however, this has been ridiculous.
0 · Reply
FE123
FE123 Jul. 15 at 6:34 PM
$VRNA $REPL can we be the Next $VRNA
0 · Reply
Naya_superStar
Naya_superStar Jul. 15 at 6:24 PM
$VRNA Watching the tape on WKSP - bulls straight up winning the war 🔥 Just saw 10.6K slapped at $4.00 - that’s size, that’s intent Buyers holding the line, sellers getting soaked $4.00 turning into demand zone in real time This ain’t random - that’s the kind of flow that starts moves If we get volume follow-up, lights out NFA but I’m leaning in heavy 🚀💥
0 · Reply
FreedSage2013
FreedSage2013 Jul. 15 at 3:23 PM
$CAPR $SLS $CRCL $CADL $VRNA SHE MADE A NEW ACCOUNT! EVERYONE REPORT IT!!!!
3 · Reply
p0ppycampbell
p0ppycampbell Jul. 15 at 1:53 PM
$CAPR $SLS $CRCL $CADL $VRNA Those investors can’t be saved, they’ll learn from the consequences.
3 · Reply
Latest News on VRNA
VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA

Jul 12, 2025, 9:09 PM EDT - 4 days ago

VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA

MRK

Major deals involving U.S. drugmakers and biotechs over the past decade

Jul 9, 2025, 1:46 PM EDT - 7 days ago

Major deals involving U.S. drugmakers and biotechs over the past decade

MRK

Merck to Buy Verona Pharma for Around $10 Billion

Jul 9, 2025, 12:36 PM EDT - 7 days ago

Merck to Buy Verona Pharma for Around $10 Billion

MRK

Two big reasons why buying Verona was crucial for Merck

Jul 9, 2025, 10:38 AM EDT - 7 days ago

Two big reasons why buying Verona was crucial for Merck

Merck has struck a roughly $10 billion deal to buy Verona Pharma

Jul 9, 2025, 10:36 AM EDT - 7 days ago

Merck has struck a roughly $10 billion deal to buy Verona Pharma

MRK

Verona Pharma shares jump with Merck set to acquire company in $10 billion deal

Jul 9, 2025, 8:13 AM EDT - 7 days ago

Verona Pharma shares jump with Merck set to acquire company in $10 billion deal

Merck dives into COPD treatments with $10 billion purchase of Verona Pharma

Jul 9, 2025, 7:48 AM EDT - 7 days ago

Merck dives into COPD treatments with $10 billion purchase of Verona Pharma

MRK

Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck.

Jul 9, 2025, 7:14 AM EDT - 7 days ago

Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck.

MRK

Merck to Buy Verona Pharma in $10 Billion Deal

Jul 9, 2025, 6:48 AM EDT - 7 days ago

Merck to Buy Verona Pharma in $10 Billion Deal

MRK

Merck to acquire Verona Pharma for $10 billion

Jul 9, 2025, 6:39 AM EDT - 7 days ago

Merck to acquire Verona Pharma for $10 billion

MRK

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

Jul 9, 2025, 6:30 AM EDT - 7 days ago

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

MRK

Merck nears $10 billion deal for respiratory drugmaker Verona, FT reports

Jul 9, 2025, 1:09 AM EDT - 7 days ago

Merck nears $10 billion deal for respiratory drugmaker Verona, FT reports

MRK

Verona Pharma: A Blockbuster Franchise In The Making

Jun 10, 2025, 1:17 AM EDT - 5 weeks ago

Verona Pharma: A Blockbuster Franchise In The Making

Mizuho's Jared Holz details potential biotech, pharma acquisitions

Jun 4, 2025, 6:10 PM EDT - 6 weeks ago

Mizuho's Jared Holz details potential biotech, pharma acquisitions

INSM LEGN

Verona Pharma Announces June 2025 Investor Conference Participation

May 21, 2025, 6:00 AM EDT - 2 months ago

Verona Pharma Announces June 2025 Investor Conference Participation

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

May 6, 2025, 6:00 AM EDT - 2 months ago

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

Silencing The Doubters: Verona Pharma Could Be Sitting On A Blockbuster

May 1, 2025, 8:51 AM EDT - 2 months ago

Silencing The Doubters: Verona Pharma Could Be Sitting On A Blockbuster

Verona Pharma plc (VRNA) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 3:45 PM EDT - 2 months ago

Verona Pharma plc (VRNA) Q1 2025 Earnings Call Transcript

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 29, 2025, 6:00 AM EDT - 2 months ago

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Verona Pharma's Bull Case Holds, But Lifecycle Extension Is Critical

Apr 7, 2025, 10:47 AM EDT - 3 months ago

Verona Pharma's Bull Case Holds, But Lifecycle Extension Is Critical

Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS

Mar 28, 2025, 7:00 AM EDT - 3 months ago

Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS

Verona Pharma plc (VRNA) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 2:31 PM EST - 4 months ago

Verona Pharma plc (VRNA) Q4 2024 Earnings Call Transcript

Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 6:00 AM EST - 4 months ago

Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Verona Pharma Announces March 2025 Investor Conference Participation

Feb 18, 2025, 6:00 AM EST - 5 months ago

Verona Pharma Announces March 2025 Investor Conference Participation

Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

Feb 13, 2025, 6:00 AM EST - 5 months ago

Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited

Jan 8, 2025, 1:45 PM EST - 6 months ago

Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited

Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights

Jan 7, 2025, 6:00 AM EST - 6 months ago

Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights

Verona Pharma Announces December 2024 Investor Conference Participation

Nov 19, 2024, 2:00 AM EST - 8 months ago

Verona Pharma Announces December 2024 Investor Conference Participation

Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value

Nov 9, 2024, 8:23 AM EST - 8 months ago

Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value

Verona Pharma to Present at Jefferies London Healthcare Conference

Nov 5, 2024, 2:00 AM EST - 9 months ago

Verona Pharma to Present at Jefferies London Healthcare Conference

Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 11:47 AM EST - 9 months ago

Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 2:00 AM EST - 9 months ago

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 21, 2024, 2:00 AM EDT - 9 months ago

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

Oct 8, 2024, 5:00 AM EDT - 10 months ago

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

ENTO OCS ONCO

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024

Sep 30, 2024, 2:00 AM EDT - 10 months ago

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024

Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care

Sep 14, 2024, 4:20 AM EDT - 10 months ago

Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

Sep 5, 2024, 2:00 AM EDT - 11 months ago

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

Top 3 Health Care Stocks That May Crash In August

Aug 14, 2024, 8:35 AM EDT - 1 year ago

Top 3 Health Care Stocks That May Crash In August

CAH CPRX

Verona Pharma plc (VRNA) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 1:15 PM EDT - 1 year ago

Verona Pharma plc (VRNA) Q2 2024 Earnings Call Transcript

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Top 3 Health Care Stocks You May Want To Dump This Quarter

Jul 30, 2024, 10:13 AM EDT - 1 year ago

Top 3 Health Care Stocks You May Want To Dump This Quarter

CPRX VRDN

Verona Pharma to Present at 44th Annual Canaccord Growth Conference

Jul 30, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma to Present at 44th Annual Canaccord Growth Conference

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jul 25, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition

Jun 30, 2024, 9:00 AM EDT - 1 year ago

Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition

First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product

Jun 27, 2024, 9:49 AM EDT - 1 year ago

First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product

Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month

Jun 27, 2024, 9:03 AM EDT - 1 year ago

Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month

US FDA approves Verona Pharma's therapy for 'smoker's lungs'

Jun 26, 2024, 5:13 PM EDT - 1 year ago

US FDA approves Verona Pharma's therapy for 'smoker's lungs'

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

Jun 26, 2024, 4:57 PM EDT - 1 year ago

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

Jun 24, 2024, 4:51 AM EDT - 1 year ago

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

MRK NTLA ARWR XFOR

Dark_Horse_Investments
Dark_Horse_Investments Jul. 17 at 12:44 AM
$VRNA what joke is Jim Cramer! First burn VRNA caller by saying sell : "co looses a lot of money". Now after a $10B takeout he wants to be in the VRNA conversation. This is why ALWAYS Do your Due Diligence. NEVER trust pundits or analysts of the the bat. https://finance.yahoo.com/news/verona-pharma-plc-vrna-unlikely-180443309.html
0 · Reply
WAJeff
WAJeff Jul. 16 at 2:48 PM
More $HOOD sold at $104. #1 realized gainer ytd, then $GEV and $VRNA (Merck buyout at $107 a share)
0 · Reply
YungBullHOLLA
YungBullHOLLA Jul. 16 at 2:28 PM
$VRNA wish I could holla more
4 · Reply
Kingjake26
Kingjake26 Jul. 16 at 1:49 PM
$IXHL The global market for obstructive sleep apnea (OSA) devices is experiencing substantial growth, driven by increasing awareness, rising prevalence of OSA, and technological advancements. The market is projected to reach $18.30 billion by 2032, with a compound annual growth rate (CAGR) of 8.6% from 2025. North America currently dominates the market, but Asia Pacific is expected to grow the fastest. $XBI $VRNA
1 · Reply
FE123
FE123 Jul. 16 at 9:33 AM
$REPL $VRNA was at $15 after Approval now $105 Sold! $REPL can follow the Same path!
1 · Reply
DipinDipout
DipinDipout Jul. 15 at 9:55 PM
$VRNA has this forum turned into the new promotional thread for stock whisperers to pump on? What the what, enough already…drop a note if you’re so inclined however, this has been ridiculous.
0 · Reply
FE123
FE123 Jul. 15 at 6:34 PM
$VRNA $REPL can we be the Next $VRNA
0 · Reply
Naya_superStar
Naya_superStar Jul. 15 at 6:24 PM
$VRNA Watching the tape on WKSP - bulls straight up winning the war 🔥 Just saw 10.6K slapped at $4.00 - that’s size, that’s intent Buyers holding the line, sellers getting soaked $4.00 turning into demand zone in real time This ain’t random - that’s the kind of flow that starts moves If we get volume follow-up, lights out NFA but I’m leaning in heavy 🚀💥
0 · Reply
FreedSage2013
FreedSage2013 Jul. 15 at 3:23 PM
$CAPR $SLS $CRCL $CADL $VRNA SHE MADE A NEW ACCOUNT! EVERYONE REPORT IT!!!!
3 · Reply
p0ppycampbell
p0ppycampbell Jul. 15 at 1:53 PM
$CAPR $SLS $CRCL $CADL $VRNA Those investors can’t be saved, they’ll learn from the consequences.
3 · Reply
Datum
Datum Jul. 15 at 1:47 PM
$VRNA the only pharma I'm even considering right now is $NVO. Taking a break from this volatility and the binary event investing in these early stage companies.
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jul. 15 at 6:41 AM
$VRNA P3 Results for SLS, AML Immunotherapy for remission maintenace, incoming Any Day Now,and due to be spectacular. anyone here have an idea of the registrational readout on the share price? what happened here when the trial data was released?
0 · Reply
Kingjake26
Kingjake26 Jul. 14 at 10:46 PM
$VRNA I have decided to put most mine in $CADL also $SNDX and have cash on the sidelines to add to my position at $CAPR when they release data or find out about type A meeting with FDA
3 · Reply
StocketShip
StocketShip Jul. 14 at 8:56 PM
$VRNA Put all my money I made now on TNXP for hopefully an even bigger August payday!!!$$$
1 · Reply
starletistrading1
starletistrading1 Jul. 14 at 12:07 PM
$VRNA are we supposed to hold these shares if the company was bought out?
2 · Reply
JarvisFlow
JarvisFlow Jul. 14 at 11:30 AM
HC Wainwright & Co. has adjusted their stance on Verona Pharma ( $VRNA ), setting the rating to Neutral with a target price of 90 → 107.
1 · Reply
Datum
Datum Jul. 14 at 1:36 AM
$VRNA is anyone buying merck stock as a way to continue following the success of ohtuvayre? If this drug is as succesful as we all hoped it would be, it should be moving the needle for merck.
2 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jul. 13 at 9:42 PM
The $VRNA M&A exit within 13 months of FDA approval underscores the overwhelming history the sooner new comm'l-stage bios exit the better for shareholders. The attachment lists all new comm'l-stage bio M&A for those with 1st approvals since 1/1/12. Of the 16 oncology focused M&A sales where shareholders saw gains, 14 were sold within 2 years. 7 of the 8 sold at losses (v. share prices at FDA approval) waited more than 2 years to sell. The phenomenon is the same in commercial-stage non-oncology except the window is 3 years. 2 of every 3 that have not been sold (i.e. M&A candidates) trade lower today than at the time of FDA approval. $BPMC is an outlier that waited over 2 years from 1st approval to sell. However, BPMC did sell within 2 years of Ayvakit's expansion into ISM (its biggest TAM). Even TSRO sold within 2 years of Zejula's approval (its biggest TAM) so the outliers do not appear true outliers. Of course things change too. This is not investment advice. $INSM $SLNO $INSM
3 · Reply
Fingerlickengood
Fingerlickengood Jul. 13 at 7:56 PM
$CDXS Interesting timing and coincidence considering $MRK just acquired $VRNA for $10B and Verona's Ohtuvayre (ensifentrine) 'a novel small molecule' was recently FDA approved for the treatment of COPD among other potential lung diseases. https://www.contractpharma.com/breaking-news/merck-agrees-to-acquire-verona-pharma-for-10b/
1 · Reply
Trainguy1
Trainguy1 Jul. 12 at 6:06 PM
$VRNA Here is a newspaper’s take on the acquisition. https://amp.newsobserver.com/news/business/article310306465.html
1 · Reply
Trainguy1
Trainguy1 Jul. 12 at 3:30 PM
$VRNA Regarding Merck’s buyout offer of Verona Pharma, Google AI reports that “The transaction is structured as a scheme of arrangement under UK law and is expected to close in the fourth quarter of 2025.” So, the $107 value should be reached by the end of the year, and possibly by early October.
0 · Reply
Jakeipedia
Jakeipedia Jul. 12 at 1:03 PM
$VRNA what a massive windfall!!! I’m holding till close Next load for me $MLYS watching $NAMS because of the leadership. Any biotech ideas please share.
2 · Reply